A surge in Covid-19 cases following the emergence of the highly transmissible delta variant has sparked fresh health concerns and raised questions about the safety and pace of reopening, even in places where vaccination rates are high such as the UK Sam Fazeli, a Bloomberg Opinion contributor who covers the pharmaceutical industry for Bloomberg Intelligence, answers questions about
